# PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

> **NCT00446446** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 52 (actual)

## Conditions studied

- Cancer
- Carcinoma
- Head and Neck Cancer
- Metastases
- Metastatic Cancer
- Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
- Oncology
- Squamous Cell Carcinoma
- Tumors

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT00446446
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-30
- **Primary completion:** 2010-12-15
- **Final completion:** 2017-11-29
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446446, "PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00446446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*